Willoughby Jane, Griffiths Jordana, Tews Ivo, Cragg Mark S
Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
Antibody & Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK; Biological Sciences, Life Science Building, University of Southampton, Highfield Campus, SO17 1BJ, UK.
Mol Immunol. 2017 Mar;83:13-22. doi: 10.1016/j.molimm.2017.01.006. Epub 2017 Jan 13.
OX40 is a type 1 transmembrane glycoprotein, reported nearly 30 years ago as a cell surface antigen expressed on activated T cells. Since its discovery, it has been validated as a bone fide costimulatory molecule for T cells and member of the TNF receptor family. However, many questions still remain relating to its function on different T cell sub-sets and with recent interest in its utility as a target for antibody-mediated immunotherapy, there is a growing need to gain a better understanding of its biology. Here, we review the expression pattern of OX40 and its ligand, discuss the structure of the receptor:ligand interaction, the downstream signalling it can elicit, its function on different T cell subsets and how antibodies might engage with it to provide effective immunotherapy.
OX40是一种1型跨膜糖蛋白,近30年前作为活化T细胞上表达的细胞表面抗原被报道。自发现以来,它已被确认为T细胞的真正共刺激分子和肿瘤坏死因子受体家族的成员。然而,关于其在不同T细胞亚群上的功能仍有许多问题,并且随着最近对其作为抗体介导免疫治疗靶点的效用的关注,越来越需要更好地了解其生物学特性。在此,我们综述OX40及其配体的表达模式,讨论受体-配体相互作用的结构、它能引发的下游信号传导、其在不同T细胞亚群上的功能以及抗体如何与之结合以提供有效的免疫治疗。